RBC Capital Markets acted as Joint Bookrunner in a $70 million Initial Public Offering for Molecular Insight Pharmaceuticals, Inc.

Transaction Information On February 2, 2007, Molecular Insight Pharmaceuticals, Inc. successfully priced an Initial Public Offering of 5.0 million shares (all primary) at $14.00 per share, within the original filing range of $14.00 to $16.00 per share, for a total offering size of $70.0 million. This was only the 4th IPO since 2005 in the life sciences domain to price within the IPO filing range. Molecular Insight Pharmaceuticals intends to use the proceeds to support clinical and regulatory development of its product candidates Azedra, Onalta and Zemiva. RBC acted as a Joint-Bookrunner on this transaction. About Molecular Insight Pharmaceuticals Molecular Insight Pharmaceuticals is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve patient healthcare by addressing significant unmet needs. The Company is focused on discovering, developing and

commercializing innovative and targeted radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Molecular Insight's lead radiotherapeutic product candidates, Azedra and Onalta, are under development for the treatment of cancer. The Company's lead molecular imaging pharmaceutical product candidate, Zemiva, is under development for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the Company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

Molecular Insight Pharmaceuticals is listed on the NASDAQ under the symbol "MIPI".

Summary Terms

Initial Public Offering

Offering Size:	$70.0 million
Price:	$14.00 per share
Initial Filing Range	$14.00 - $16.00 per share
Pre-Money Value:	$275.3 million
Post-Money Value	$345.3 million

Investment Banking Contact

Simon Gill

Managing Director, U.S. Healthcare

212-428-6521

simon.gill@rbccm.com